| 7/29/2015 | BKCVHY | S&P upgrades Salix
|
| 4/1/2015 | CVLM | Salix convertible noteholders get change-of-control put option
|
| 3/16/2015 | CV | Market Commentary: Salix convertibles add on sweetened Valeant deal; Amarin extends gains; Actavis in action
|
| 3/16/2015 | CV | Market Commentary: Morning Commentary: Salix trades actively on sweetened Valeant deal; SanDisk, Tesla in action
|
| 3/12/2015 | BKCVDDEMIGPV | Market Commentary: United Rentals two-parter, CenturyLink price; Valeant upsizes; funds lose $1.96 billion
|
| 3/11/2015 | BKCVDDEMIGPV | Market Commentary: Shea Homes two-parter, Surgical Care, GFL deals price; Valeant up on Endo bid for Salix
|
| 2/25/2015 | CVLM | Salix notifies 2.75% convertible holders of expected make-whole change
|
| 2/24/2015 | BKCVDDEMIGPV | Market Commentary: Digicel drives by, moves up; recent bonds busy; Sitel bonds gain as Onex eyes possible sale
|
| 2/23/2015 | BKCVDDEMIGPV | Market Commentary: DISH weakens after numbers, CEO retirement; Salix gains on Valeant merger; Toys’ bonds up
|
| 2/23/2015 | CV | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
| 2/23/2015 | BKCVHY | Moody’s could raise Salix
|
| 2/23/2015 | CV | Market Commentary: Morning Commentary: Salix trades actively, lower on merger news; Spectrum sinks on patent ruling
|
| 2/3/2015 | CV | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
| 12/4/2014 | CV | Market Commentary: NXP Semiconductors extends gains; energy sector heavy; ANI Pharmaceuticals on tap
|
| 11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
| 11/10/2014 | CV | Market Commentary: Morning Commentary: Dendreon drops after bankruptcy filing; Salix Pharmaceuticals bounces slightly
|
| 11/7/2014 | CV | Market Commentary: Salix Pharmaceuticals slumps outright, adds on heavy deltas; Allcripts Healthcare drops
|
| 11/7/2014 | BKCVHY | Moody’s reviews Salix
|
| 11/7/2014 | BKCVHY | S&P lowers Salix, debt
|
| 11/7/2014 | CV | Market Commentary: Morning Commentary: Salix slumps on earnings miss, lowered guidance; AllScripts Healthcare drops
|
| 11/6/2014 | CV | Market Commentary: LinkedIn gains after pricing at cheap end; Aegerion regains ground; Salix shares plunge
|
| 10/3/2014 | CV | Market Commentary: Downsized Starwood edges up from discount; Salix flat to lower; Red Hat extends gains
|
| 10/3/2014 | CV | Market Commentary: Morning Commentary: Downsized Starwood rises from discount; Salix flat to lower; Red Hat up
|
| 9/23/2014 | CV | Market Commentary: Tesaro looks rich at the mids; Salix up in line or better amid M&A talk; SolarCity on tap
|
| 9/23/2014 | CV | Market Commentary: Morning Commentary: Planned Tesaro looks rich on the mids; Salix active amid more M&A chatter
|
| 8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
| 8/19/2014 | CV | Market Commentary: Salix surges on takeout rumors; Illumina paper trades actively; PDL BioPharma in line
|
| 7/9/2014 | CV | Market Commentary: Market quiet as focus shifts to earnings; Accuray sees outright interest; Salix in line
|
| 7/1/2014 | CV | Market Commentary: New Starwood Waypoint adds; Salix jumps outright, flat on hedge; Tower active; Ctrip eyed
|
| 7/1/2014 | CV | Market Commentary: Morning Commentary: Upsized Starwood Waypoint adds on debut; Salix jumps outright, flat on hedge
|
| 2/18/2014 | CV | Market Commentary: Convertibles thinly traded to start week; Ctrip.com paper higher in line; Chemed expands
|
| 1/13/2014 | CV | Market Commentary: Goldcorp acquisition spurs Detour Gold, other miners; EnPro jumps outright; Tower weaker
|
| 12/2/2013 | BKCVHY | Moody's rates Salix loans Ba1, notes B2
|
| 12/2/2013 | BKCVHY | S&P assigns BB to Salix loan, gives B to notes
|
| 6/10/2013 | CV | Market Commentary: Convertibles quiet, weaker; Ryland under pressure; Cornerstone OnDemand, Workday on tap
|
| 5/13/2013 | CV | Market Commentary: Endo Health 'comes in' on FDA news; Theravance still trades mixed; Shutterfly on deck
|
| 5/10/2013 | CV | Market Commentary: Theravance mixed on COPD drug approval; Meritor improves; Electronic Arts extends gains
|
| 4/16/2013 | CV | Market Commentary: NetApp active, in line with shares; Intel trades ahead of earnings; Chemed flat to higher
|
| 5/8/2012 | CV | Market Commentary: Thompson Creek slides; Annaly on tap; Dendreon drops outright, on hedge; Salix seen flat
|
| 3/26/2012 | CV | Market Commentary: Investment-grade issues dominate convertibles market; Medtronic higher; MF Global dips
|
| 3/16/2012 | CV | Market Commentary: Convertibles slightly weaker; Salix lower; Alliant Techsystems adds on hedge; DryShips up
|
| 3/16/2012 | CV | Salix greenshoe exercised; 1.5% convertibles lifted to $690 million
|
| 3/15/2012 | CV | Market Commentary: Medivation treads water; Salix comes in on hedge since issue; Clearwire flat; Southwest adds
|
| 3/13/2012 | CV | New Issue: Salix prices upsized $600 million seven-year convertibles to yield 1.5%, up 35%
|
| 3/13/2012 | CV | Market Commentary: New Salix pops, then retreats on debut; Medivation talk revised; Wintrust notes to price
|
| 3/12/2012 | CV | Market Commentary: Salix Pharmaceuticals, Medivation to price; Suntech Power slips; Central European extends gains
|
| 3/12/2012 | CV | Salix talks $500 million seven-year convertibles at 1.5%-1.75%, up 35%
|
| 11/9/2011 | CV | Market Commentary: Rovi gains dollar neutral as dour outlook torpedoes stock; Salix adds outright; GM lower
|
| 2/24/2011 | CV | Market Commentary: Salix lower on hedge on drug setback; Newmont Mining drops in line after earnings released
|
| 6/3/2010 | CV | Salix greenshoe exercise lifts 2.75% convertibles to $345 million
|
| 5/28/2010 | CV | New Issue: Salix details upsized $300 million five-year convertibles, priced to yield 2.75%, up 30%
|
| 5/28/2010 | CV | Market Commentary: Transocean slips with sector; Salix gains on debut; tough month for convertibles trading
|
| 5/27/2010 | CV | New Issue: Salix prices upsized $300 million five-year convertibles to yield 2.75%, up 30%
|
| 5/27/2010 | CV | Market Commentary: Transocean rises, then pares gains; SunPower, NetApp up; Salix sells upsized $300 million
|
| 11/17/2009 | CV | Salix Pharmaceuticals files automatic shelf for stock and preferreds
|
| 8/22/2008 | CV | Salix greenshoe fully exercised, lifts 5.5% 20-year convertibles to $60 million
|
| 8/18/2008 | CV | New Issue: Salix prices upsized $55 million 20-year convertibles to yield 5.5%, up 20%
|
| 8/18/2008 | CV | Market Commentary: Fannie Mae, Huntington edge lower; Amylin expands as shares sink; Cheniere places private deal
|
